What is the global market size of Bipolar Disorder Market?

Bipolar Disorder Market size was valued at USD 5.25 billion in 2021 and is poised to grow from USD 5.36 billion in 2022 to USD 6.4 billion by 2030, growing at a CAGR of 2.00% in the forecast period (2023-2030).

Which region accounted for the largest share in Global Bipolar Disorder Market?

Geographically, North America is anticipated to dominate the global bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the global market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs), By Type(Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Others), By Region - Industry Forecast 2025-2032

Q: Who are the key vendors in the Global Bipolar Disorder Market?

Global bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Allergan (Ireland)', 'AstraZeneca plc', 'Bristol Myers Squibb Company', 'Eli Lilly and Company', 'GlaxoSmithKline plc', 'H. Lundbeck A/S', 'Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)', 'Otsuka Holdings Co. Ltd.', 'Pfizer Inc.', 'Sunovion Pharmaceuticals Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Takeda Pharmaceutical Company Limited', 'Abbott Laboratories', 'Novartis International AG', 'Alkermes plc', 'AbbVie Inc.', 'Merck & Co. Inc.', 'Mylan N.V.', 'Neurocrine Biosciences Inc.', 'Vanda Pharmaceuticals Inc.'.

Report ID: SQMIG35I2095 | Region: Global | Published Date: July, 2001
Pages: 157 | Tables: 67 | Figures: 75

Bipolar Disorder Market News

In January 2022, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the antipsychotic Caplyta (lumateperone) for the treatment of bipolar I and II depression in adults. Caplyta, marketed by Intra-Cellular Therapies Inc., was already approved for the treatment of schizophrenia in adults.
In June 2021, Through the multi-stage ENLIGHTEN clinical trials, the Food and Drug Administration (FDA) approved Lybalvi® (olanzapine/samidorphan) for a number of indications, including the treatment of adults with schizophrenia and/or bipolar I disorder (acute manic episodes or acute episodes with mixed features). Olanzapine/safety samidorphan's and effectiveness were examined over studies lasting 4 weeks, 24 weeks, and 52 weeks, respectively. The secondary analysis further assessed the metabolic consequences.

Bipolar Disorder Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Bipolar Disorder Market size was valued at USD 5.25 billion in 2019 and is poised to grow from USD 5.36 billion in 2023 to USD 6.4 billion by 2031, growing at a CAGR of 2.00% in the forecast period (2024-2031).

bipolar disorder market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions. 'Allergan (Ireland)', 'AstraZeneca plc', 'Bristol Myers Squibb Company', 'Eli Lilly and Company', 'GlaxoSmithKline plc', 'H. Lundbeck A/S', 'Janssen Pharmaceuticals Inc. (a subsidiary of Johnson & Johnson)', 'Otsuka Holdings Co. Ltd.', 'Pfizer Inc.', 'Sunovion Pharmaceuticals Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Takeda Pharmaceutical Company Limited', 'Abbott Laboratories', 'Novartis International AG', 'Alkermes plc', 'AbbVie Inc.', 'Merck & Co. Inc.', 'Mylan N.V.', 'Neurocrine Biosciences Inc.', 'Vanda Pharmaceuticals Inc.'

The market for treating bipolar illness is anticipated to rise over the forecast period as key players concentrate on expanding their product portfolio through an increase in the launches and approvals of new pharmaceuticals for the condition. For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved Allergan plc and Gedeon Richter plc's supplemental new drug application (sNDA) for VRAYLAR (cariprazine), an oral, once-daily atypical antipsychotic drug for the expanded use and treatment of depressive episodes related to bipolar I disorder (bipolar depression) in adults.

Rising cases of mental illness: As non-ambiguous cases of illness have been increasingly prevalent in the population, bipolar disorder in children and adolescents has become a common diagnosis.

Geographically, North America is anticipated to dominate the bipolar disorder market due to the region's high levels of stress and widespread substance misuse problems. Various government programmes and efforts meant to increase awareness fuel the rise of the market in Europe and North America. The North America region demonstrated its dominance by accounting for over 50% of the market for bipolar disorder in 2019 and anticipated for the forecast period. The market demand is significantly rising due to the Y-O-Y increase in the prevalence of bipolar disorder in this region. The prevalence of bipolar disorder is rising in the North America, which is driving the regional market. A sizeable portion of the population in this region has high levels of stress and sleep problems.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Bipolar Disorder Market Size, Share, Growth Analysis, By Drug Class(Mood Stabilizers, Anticonvulsants, Antipsychotic Drugs, Antidepressant Drugs), By Type(Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, Others), By Region - Industry Forecast 2025-2032

Bipolar Disorder Market News

Bipolar Disorder Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Bipolar Disorder Market?

Who are the key vendors in the Bipolar Disorder Market?

What is the key driver of Bipolar Disorder Market?

What is the key market trend for Bipolar Disorder Market?

Which region accounted for the largest share in Bipolar Disorder Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300